The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' pill, Journavx, for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...

For example, the Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) share price is up 83% in the last five years, slightly above the market return. Over the last year the stock price is up ...

Wall Street sees plenty of growth ahead, projecting an 8.2% jump in sales for 2025 as new products gain traction ... dollar markets, Vertex offers a compelling mix of stability and upside potential.